DIAGNOS announces extension of contract with Novo Nordisk for follow-up of diabetic patients undergoing treatment with drugs included in the therapeutic portfolio

BROSSARD, Quebec, April 26, 2022 (Globe Newswire) – Diagnostics Inc. (” Diagnosing the cause “, The” Institution Or “we”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection of serious health conditions through its Artificial Intelligence (AI) technology FLThere isRE is pleased to announce the extension of the contract for follow-up of diabetic patients undergoing treatment with drugs included in Novo Nordisk’s therapeutic portfolio.

Novo Nordisk’s therapeutic portfolio reduces the risk of retinopathy and offers positive benefits by reducing the risk of major cardiovascular events such as heart disease, stroke or even death.

“We are delighted to announce the extension of the Extended Agreement with Novo Nordisk in Mexico, powered by CARA (Computer Assisted Retinal Analysis), Diagnostics’ artificial intelligence. Our expertise in innovative artificial intelligence and non-invasive eye screening will enable specialists to observe retinal analysis of diabetic patients treated with Novo Nordisk drugs so that the positive effects of their treatment are not only on them but also on them. On high blood pressure, the use of diagnostic technology leads to the establishment of future measures to reduce the risk of major cardiovascular disease (CVD), “said Mr. Andre Laurente, President of Diagnostics.

“Use artificial intelligence based on in-depth learning algorithms to improve patient follow-up and condition by providing better medical care. Photo)) which we use for retinopathy screening, allows us to detect early abnormalities of the retinal microvascularity and provide a cardiovascular risk score aimed at reducing the morbidity and mortality of at-risk populations, “he said. Dr. Hadi Chakor, Medical Director of Diagons. “In six months, we will follow the evolution of two complex chronic diseases in 500 patients, thanks to our non-invasive artificial intelligence technology: a screening at the beginning of the program and a second screening 6 months later.

About Novo Nordisk
Novo Nordisk is a global healthcare organization with over 90 years of innovation and leadership in diabetes care. This tradition has given us the experience and ability to help people overcome other serious chronic diseases: hemophilia, growth disorder and obesity. Located in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries.

Per Related Of Diagnosing the cause
DIAGNOS is a publicly traded Canadian company that aims to initially detect serious health problems using its artificial intelligence (AI) platform FLAIRE. Makes applications like FLAIRE CARA (Computer Assisted Retina Analysis) faster change and development. CARA’s image enhancement algorithms make sharp, clear and retinal images easier to analyze. CARA is a low cost tool used for real-time screening of many patients. CARA sales clearance has been granted by the following regulatory bodies; Health Canada, FDA (United States), CE (Europe), Coffepris (Mexico), and Saudi FDA (Saudi Arabia).

More information is available on the websites www.diagnos.com And www.sedar.com.

This press release contains information from the front. There is no guarantee that the information on the front will prove to be accurate, as actual results and future events may differ materially from those expected in such statements. DIAGNOS disclaims any intention or obligation to publicly update or correct new information, future events or any other far-sighted information as a result. The advance information contained in this press release is clearly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its regulation service provider (as the term is defined in the TSX Venture Exchange Policy) assumes responsibility for the adequacy or accuracy of this release.

CONTACT: Pour plus d’informations sur ce communiqué, veuillez communiquer avec :

M. André Larente, président
Diagnos Inc.
Tél : +1 450-678-8882, poste 224
Courriel : alarente@diagnos.ca

Communications Corporatives:
Nancy Massicotte
IR Pro Communications Inc.
Tél: +1 604-507-3377
Sans frais : 1-866-503-3377
Courriel: nancy@irprocommunications.com

Source: https: //www.globenewswire.com/news-release/2022/04 …

Leave a Comment